← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expands subcutaneous monotherapy for eligible MSI-high or mismatch repair-deficient colorectal cancer to patients age 12 years or older who weigh at least 30 kg: after IV nivolumab plus ipilimumab in unresectable or metastatic disease, or after specified fluoropyrimidine, oxaliplatin, and irinotecan in metastatic disease.

LAMPGEN ANALYSIS

Why it matters

The pediatric label extension covers two distinct routes into subcutaneous treatment, with the same age and minimum weight.

What research teams should watch

Verify the dosing weight, biomarkers and qualifying prior regimen; coordinate use with a pediatric oncology team.

PRIMARY RECORDS

Sources